1.12.1

News

30 Aug 16
Arbutus terminates license agreement for VLP platform for the treat-ment of hepatitis B infections
Schlieren (Zurich), Switzerland, August 30, 2016 – Kuros Biosciences announced today that it was informed by Arbutus Biopharma Inc. about the decision to terminate an exclusive license agreement with former Cytos Biotechnology Ltd., a......READ MORE
10 Aug 16
Kuros appoints Philippe Saudan as Chief Development Officer
Schlieren (Zurich), Switzerland - Kuros Biosciences announced today that Dr. Philippe Saudan has been appointed Chief Development Officer and member of the Executive Board with immediate effect. Dr. Saudan has spent the last 16 years in the......READ MORE
28 Jun 16
valuationLAB Initiates Research Coverage on Kuros
Schlieren (Zurich), Switzerland, June 28, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that independent life science research boutique valuationLAB has issued its first report on Kuros. The research analyst estimates a current......READ MORE
CMS - 1.12.1 - Rontiki
 

Copyright statement

 

Previous page: Location